Background: Treatment of relapsed childhood acute lymphoblastic leukemia (ALL) is particularly challenging due to the high treatment intensity needed to induce and sustain a second remission.
INTRODUCTION
Following the dramatic changes in outcome in the 1960s and 1970s, survival in childhood acute lymphoblastic leukemia (ALL) has continued to improve and is now over 90%. [1] [2] [3] [4] [5] These results are mostly due to the intensification of chemotherapy, better supportive care, and advances in allogeneic hematopoietic stem cell transplantation (HSCT). Nevertheless, relapse remains a challenge since it occurs in 8-20% of patients in first remission and only half is expected to survive long term. [6] [7] [8] [9] [10] [11] For each patient with ALL, the road to longterm survivorship is long and is often complicated with serious side effects of the treatment. During primary treatment for ALL, 1.5-5% of the patients die of treatment-related complications, most commonly infections. 3, [12] [13] [14] [15] Patients with relapse are more susceptible to the adverse effects of chemotherapy because of the cumulative effect of organ toxicities and the high treatment intensity. 16 Furthermore, a higher proportion of patients undergo allogeneic HSCT in second complete remission (CR2), where prolonged severe immunosuppression and graft versus host disease (GVHD) further increase the risk of lifethreatening events. Careful selection of patients for the most appropriate treatment intensity is important since overtreatment increases the risk of treatment-related mortality (TRM) and second malignancies (SMNs), whereas undertreatment may result in refractory leukemia and subsequent relapses. This is, to our knowledge, the first population-based study on TRM in relapsed childhood ALL. The aims were to investigate the causes of death in patients with first relapse during or after common upfront Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL treatment and to identify risk factors associated with TRM.
PATIENTS AND METHODS
From 1992, all children 1.0-14.9 years of age with pre-B and T-cell ALL in the Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) have been enrolled in population-based consecutive NOPHO clinical trials. Eligible for this study were all patients who experienced a relapse as the first event (n = 485) in the NOPHO ALL-92 (n = 324) and ALL-2000 (n = 161) trials. Patients who relapsed after undergoing HSCT in first complete remission were not eligible since these patients are invariably excluded from relapse protocols and have a uniformly dismal prognosis. Two patients, both with Down syndrome (DS), were excluded since they did not receive relapse treatment with curative intent. Data were extracted from the NOPHO ALL registry. Relapses occurring before January 2012 were included and all events occurring before January 2016 were used in the outcome analyses. In cases where the registration of relapse treatment, outcome, follow-up status, or the cause of death was incomplete, supplementary data were requested from the treating hospitals. All cytogenetic data were centrally reviewed by the NOPHO Cytogenetic Working Group. 
Definitions
There are no universal definitions of TRM. 17, 18 We used the recently developed International Pediatric Oncology Mortality Classification Group description and defined TRM as any death occurring as the first event in the absence of progressive disease at the time of death. 18 All deaths after HSCT in CR2 were defined as TRM if second relapse or SMN had not occurred. The cause of death was classified either as primary, if a single event was reported by the clinician or if it was the main event causing death, or secondary when an underlying treatmentrelated condition existed, for example, GVHD. The criterion for infectious death was a clinical picture strongly indicating an infectious process and/or a microbiologically proven infection.
Treatment
A description of the risk groups and treatment used in the NOPHO ALL-92 and ALL-2000 trials as well as the long-term results were published in Leukemia 2010. 2 Furthermore, a detailed description of the prognostic factors, treatment, and outcome for relapsed ALL in the same initial cohort was recently published in Haematologica. 8 Relapse treatment was divided into four groups: ALL-REZ Berlin Frankfurt Münster (BFM) 90, 95/96 and 2002 relapse trials, 11, 19, 20 NOPHO ALL-92 and ALL-2000 High Risk arms used as relapse therapy, the Finnish Relapse in Acute Lymphoblastic Leukemia (RALLE) pilot protocol, 21 and "Other treatment". The group "Other treatment" included patients treated with combinations of protocols, the Children's Cancer and Leukemia Group (CCLG) ALLR3 relapse protocol, 10 Children's Cancer Group (CCG) relapse protocols, and nonprotocol (Table 1) , which is based on the BFM and CCLG risk group stratification.
Statistical analysis
The time to TRM was defined as the time from diagnosis of ALL relapse to death, caused by treatment complication as defined above. Risk of TRM and the generation of cumulative incidence curves for TRM were estimated taking competing risks of other second events (progressive disease, second relapse, and SMN) into account. 22 Events beyond second relapse and SMN were not analyzed further in this study. We used competing risks regression models to analyze risk factors for TRM, estimating subdistribution hazard ratios (HRs) with 95% confidence intervals. 23 To limit the number of variables and to demonstrate the effect of the risk stratification on TRM, we chose to use relapse Of the seven patients with unfavorable cytogenetics and TRM, five had received high-risk primary treatment, three relapsed very early, all had isolated bone marrow relapse, six were stratified as high-risk relapses, and five died during the induction phase of the relapse treatment. Among the seven patients with iAMP21-ALL, six were stratified as high-risk relapses, one experienced a second relapse after HSCT in CR2, one died of bacterial sepsis in CR2, and one died of fungal infection soon after HSCT in CR2. In contrast to previous findings, none of the 15 patients with DS died of treatment-related toxicities. No statistically significant differences were detected in the cumulative incidence of TRM between sex, age groups, or relapse periods (Supplementary Figure S1 ). Competing events: Progressive disease, second relapse, and second malignancy. In adjusted model, HSCT in CR2 was added as an additional competing event.
RESULTS

Treatment
Univariable analysis of risk factors for TRM
Reference groups: 1 Relapse risk group: SR (n = 21), 2 cytogenetics: normal/missing (n = 11), 3 no HSCT in CR2 (n = 28).
Multivariable analyses of risk factors for TRM
The results of the adjusted regression analyses are presented in Table 3 . In the final model, we included covariates that were strongly associated with TRM in the univariate regression, unfavorable cytogenetics, and high-risk stratification at relapse. In addition, we included HSCT in CR2 due to the known effect of HSCT on treatment-related toxicity. We tested the effect of the primary risk group on TRM in the models presented in Table 3 but in the adjusted settings, primary risk group was not an independent risk factor for TRM. There was a strong association between the primary risk group and the relapse risk group; 70% of the high-risk relapses were stratified as high risk at diagnosis. We investigated possible interactions between age (<10 years vs. ≥10 years), sex, and relapse periods (1992-2001 vs. 2002-2011 ) with other variables in our analyses but did not find any statistically significant interactions. In regression models where we estimated the effect of relapse treatment on TRM and adjusted for risk stratification at relapse, cytogenetics, and HSCT, we did not observe a statistically significant difference between the different relapse treatments, although a trend toward increased risk was observed in patients treated according to the RALLE relapse protocol (HR 2.14; 95% CI 0.98-4.69; P = 0.057) (data not shown).
Cause of death
Infections (73.1%) were the most common primary cause of death (Table 4) . Bacterial and fungal infections were the most prevalent cause of death during induction and CR2 among patients that did not undergo HSCT but viral infections were more common post-HSCT (Table 5) . GVHD was both the most common noninfectious primary cause of death and the most common secondary cause.
DISCUSSION
In the NOPHO ALL-92 and ALL-2000 trials, treatment-related complications were the cause of death in 3% of patients enrolled. 12, 13 Among the patients that relapsed, TRM was more than three times as common (10.8%) and like during the primary treatment; infections were the most common cause of death. We identified factors that were independently associated with a higher risk of TRM: unfavorable cytogenetics, high-risk stratification at relapse, and HSCT in CR2. On the contrary, factors commonly associated with TRM in children with primary ALL such as gender, age, and DS did not have a statistically significant effect on TRM in patients with relapsed ALL. 13, [24] [25] [26] Traditionally, relapse treatment protocols use rotating polychemotherapy cycles, followed by allogeneic HSCT if protocol criteria are met and a suitable donor is available but some of the more recent ALL relapse trials allocate patients to randomizations involving novel agents and therapies. 10, 19, 27 In most trials that include all types of ALL relapses, the induction and consolidation chemotherapy regimens do not differentiate between relapse risk groups. The treatment intensity prior to HSCT should therefore be similar. Nevertheless, we observed an increased risk of TRM in patients stratified as high risk at relapse regardless of HSCT. The association with high-risk relapses is not surprising since most patients stratified as high-risk relapses underwent high-risk primary treatment, experience a relapse either on treatment or soon after cessation of primary treatment and have bone marrow involvement at relapse. These patients are still under the effect of the primary treatment and full reconstitution of normal marrow function
TA B L E 4 Primary and secondary causes of death in patients that died of treatment-related complications
Cause of death Primary cause (no. of patients) Secondary cause (no. of patients) Comments
Induction death 4 Combined relapse, died the day after start of relapse treatment, and cerebral herniation secondary to increased intracranial pressure.
has not been accomplished. 28 This general vulnerability could be one of the reasons for the lack of association between age, sex, and TRM in our study.
Interestingly, patients with unfavorable cytogenetic aberrations had an increased risk of TRM. To the best of our knowledge, this is the first time this association has been described in childhood ALL, but in our previous study unfavorable cytogenetics predicted mortality after relapse. 8 We can now show that this effect was both due to an increased risk of TRM as well as progressive disease and the very poor outcome after second relapse (Supplementary Table S2 ).
Whether unfavorable cytogenetic aberrations are surrogate markers for other factors not tested in our models, if they affect treatment choices, or if the leukemic cells interact with the bone marrow and immune system differently remain open questions at this point.
Despite attempts to improve cytotoxic chemotherapy regimens for ALL relapse, the rate of second relapses is high and the overall survival is still relatively poor. In our previous study, we observed an TRM and transplant-associated morbidity are major limiting factors for use of allogeneic HSCT in the treatment of malignant hematological disorders. 29, 30 In most current ALL relapse protocols, allogeneic HSCT is the consolidation method of choice for high-risk relapses and for standard-risk relapses with poor MRD response. In this study, TRM occurred in CR2 in 6.8% patients during the chemotherapy phases of the treatment but in 11.7% patients post-HSCT. Infections were the most common cause of TRM post-HSCT but GVHD was either the primary cause (n = 4) or the secondary cause (n = 6) of death in 10 patients. Until new treatment strategies are introduced, allogeneic HSCT is the best therapy available for a large portion of ALL relapses, but due to potential treatment toxicities it should be reserved for patients where the risk of subsequent relapses outweigh the risk for TRM.
The development of novel agents and therapies specifically directed against leukemic cells is very important to improve overall survival in relapsed childhood ALL. In general, targeted therapies do not cause as severe myelotoxicity and immunosuppression as conventional chemotherapy, serious infectious complications are therefore less common. 31, 32 Severe toxicity has been described during treatment but most events have been reversible after discontinuation and with adequate supportive care. Little is known about the long-term toxicity
TA B L E 5 Etiology of infectious deaths
Type of infection Microorganism Induction phase Chemotherapy only in CR2 HSCT in CR2
Bacterial (n = 13)
Gram positive
Streptococcus pneumoniae 1
Streptococcus mitis 1
Staphylococcus aureus 1
Enterococcus faecalis 1
Bacillus cereus 1
Gram negative
Escherichia coli 1 1
Enterobacter species 1
Klebsiella pneumoniae 1
Pseudomonas aeruginosa 1
Stenotrophomonas maltophilia 1 Fungal (n = 6)
Candida albicans 1
Aspergillus species 1
Rhizomucor pusillus 1
Clinically suspected 1 2
Unknown (n = 7) 1 2 4
Total (n = 38) 10 14 14
CR2, second complete remission, HSCT, hematopoietic stem cell transplantation. of the newer novel agents and immunotherapies. 32 At present, novel agents have not proved to be sufficient as a single treatment in childhood ALL, but inclusion of targeted therapies to a less toxic backbone will hopefully reduce TRM in ALL relapse. For patients with high-risk relapses, post-HSCT relapses, or refractory disease, immunotherapy such as chimeric antigen receptor T-cells and T-cell engaging bispecific antibodies might in the near future be used to induce molecular remission and diminish the indication for allogeneic HSCT. 33, 34 Surprisingly none of the patients with DS died of treatment-related causes. In our previous study, patients with ALL relapse and DS had a poor overall survival caused by the high occurrence of second relapses. 8 This is in contrast to previous findings where patients with DS-ALL had worse outcome mainly because of the high incidence of TRM. 13, 14 Increased sensitivity to high-dose methotrexate and anthracyclines is well documented in patients with DS and infectious complications are more common. 35 This has led clinicians to modify the leukemia treatment and to be more restrictive to the use of allogeneic-HSCT. In a study by Hitzler et al., patients with DS-ALL had an inferior outcome after allogeneic-HSCT compared to non-DS-ALL mainly because of higher frequency of disease recurrence rather than TRM. 36 This illustrates well the difficulties in finding the optimal treatment intensity in patients with relapsed DS-ALL and the urgent need for the development of international trials for this subgroup of patients.
In this study, infections were the most common cause of treatment- Clinical guidelines for the management of febrile neutropenia in children with cancer and HSCT recipients have been developed and are updated regularly. 37, 38 Antimicrobial prophylaxis is used extensively in patients undergoing HSCT and antifungal prophylaxis has become the standard of care in children with acute myeloid leukemia (AML). [38] [39] [40] [41] [42] [43] Studies on antimicrobial prophylaxis in children with ALL are sparse and in contrast to AML, there is not a strong evidence for the use of antifungal prophylaxis during the primary treatment of ALL. 44 However, the sustained immunosuppression of previous leukemia treatment, profound and persistent neutropenia, and the use of systemic glucocorticoids make patients with relapsed ALL at high risk of developing invasive infections. Based on this underlying vulnerability and the lessons from previous studies on children with AML and HSCT recipients, many centers use antifungal prophylaxis in children with relapsed ALL as well. 16 Although the majority of infections that occurred during the chemotherapy phases in our study were of bacterial origin, it is difficult to conclude whether antibacterial prophylaxis would have had an impact on the frequency of fatal bacterial infections. Previous studies on both adults and children with hematological malignancies have shown conflicting results and currently there is a lack of evidence supporting antibacterial prophylaxis in children with relapsed ALL. [45] [46] [47] [48] [49] Patients undergoing allogeneic HSCT receive, in addition to antifungal prophylaxis, both antiviral and antibacterial prophylaxis during periods of prolonged neutropenia and immunosuppression. 50 Broad antimicrobial prophylaxis and the close monitoring of suspected infections could be one of the reasons for the lower frequency of TRM due to bacterial and fungal infections and a higher frequency of culture negative infections among the HSCT patients in our study. Post-HSCT patients need immunosuppression that is more directed to the cellmediated immunity to decrease the effect of GVH response, which is likely one of the main explanations for the high frequency of viral infection post-HSCT.
Historically it has been difficult to compare the risk and frequency of TRM between different studies and trials because of the lack of uniform criteria. 17, 18 In this study, we used the definition of TRM that was recently developed by the International Pediatric Oncology Mortality Classification Group. 18 In our opinion, these recommendations were easy to follow and helpful. We did not use the suggested causeof-death attribution system since the cause of death was reported by pediatric oncologist's that retrieved data from patient files. We found it useful to assign primary and secondary causes of death as a number of patients had more than one serious coexisting complication, for example, infection and GVHD. Future studies should use these recommendations to facilitate the comparison between different study cohorts.
In conclusion, TRM contributes significantly to the poor overall survival after relapsed childhood ALL. Most treatment-related deaths occur in phases of severe myelosuppression when susceptibility to invasive infections is high. The current treatment modalities used in ALL relapse are highly myelotoxic and in cases of allogeneic-HSCT, chronic inflammation and immunosuppression add to the treatment toxicity. Until targeted therapies become available for patients with ALL relapse, studies should focus on strategies to decrease the frequency of invasive infections and improve the diagnostics and treatment of febrile neutropenia, especially during periods of severe myelosuppression, in patients undergoing HSCT and in patients with high-risk characteristics.
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